Customer No: 20462

Attorney Docket No: P51339

Confirmation No: 6639

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Boehm et al.

Serial No.: 10/511,770 Group Art Unit No.: 1624

Filed: 3 March 2006 Examiner: Truong, T.

For: NOVEL COMPOUNDS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

Petitioner, SmithKline Beecham Corporation, of One Franklin Plaza, 200 North 16th Street, Philadelphia, PA, 19103, USA, represents that it is the assignee of the entire right, title, and interest in and to the above-identified application, Application No. 10/511,770 filed 3 March 2006 for NOVEL COMPOUNDS in the names of Jeffrey BOEHM, Katherine WIDDOWSON, James CALLAHAN, and Zehong WAN, as indicated by assignment(s) duly recorded in the United States Patent and Trademark Office at Reel 016897, Frame 0717 on 18 October 2005. Petitioner further represents that it is the assignee of the entire right, title, and interest in and to U.S. Patent No. 7,314,881, as indicated by assignment(s) duly recorded in the United States Patent and Trademark Office at Reel 014404 Frame 0463, on 18 April 2003.

Art Unit: 1624

To obviate a double patenting rejection, Assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application that would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior patent No. 7,314,881. Assignee hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, Assignee does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that the prior patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated before the expiration of its full statutory term as presently shortened by any terminal disclaimer.

In accordance with the fee schedule in 37 C.F.R. § 1.20(d), please charge the required fee of \$140.00 to Deposit Account No. 19-2570. Please charge any additional fees under 37 C.F.R. § 1.16 or § 1.17 which may be required by this paper, or credit any overpayment to Deposit Account No. 19-2570. If a fee is required for an extension of

- 3 —

time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

The undersigned is an attorney of record.

Respectfully submitted,

Dated: 16 April 2009

By:

Dara L. Dinner Reg. No. 33,680

Hara L. Climer

GLAXOSMITHKLINE Corp. Intellectual Property-U.S. P.O. Box 1539 King of Prussia, PA 19406-0939 (610) 270-5017 - telephone (610) 270-5090 - facsimile